In a head-to-head trial, Eli Lillys weight-loss drug Zepbound (tirzepatide) shows superiority over Novo Nordisks Wegovy (semaglutide).
FDA awards Stoke Therapeutics a breakthrough therapy designation for zorevunersen and its use in treating Dravet syndrome.
FDA warns Chinas YouQuan Care Products about CGMP violations in its manufacturing of finished drugs.
Roivants Kinevant Sciences unit halts the development of namilumab for treating sarcoidosis after a Phase 2 study failed to show treatment benefit.
FDA issues a report and plan on best practices for guidances, incorporating comments from a 2023 draft report and plan.
FDA publishes a guidance with recommendations for marketing submissions for Predetermined Change Control Plans for artificial intelligence-enabled dev...
FDA warns South Koreas LCC Ltd. about CGMP violations in its manufacturing of unapproved and misbranded over-the-counter drugs.
FDA grants Merck a breakthrough therapy designation for sacituzumab tirumotecan (sac-TMT) and its use in treating certain patients with non-small cell...
